Synapse - Works

Results (5612)

VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

Meeting Abstract

Coleman, R. L.; Fleming, G. F.; Brady, M. F.; Swisher, E.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K.; Ben-Baruch, N.; Werner, T. L.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

Meeting Abstract

Peters, S.; Ramalingam, S. S.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S. W.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; Sakai, H.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)

Meeting Abstract

González Martín, A.; Pothuri, B.; Vergote, I. B.; Christensen, R. D.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

Meeting Abstract

Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1-positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Meeting Abstract

Van Cutsem, E.; Valderrama, A.; Bang, Y. J.; Fuchs, C.; Shitara, K.; Janjigian, Y. Y.; Qin, S.; Larson, T.; Shankaran, V.; Stein, S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Motzer, R. J.; Lee, C. H.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U. N.; Graham, R.; Liu, S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

Meeting Abstract

Smith, M. R.; Sandhu, S. K.; Kelly, W. K.; Scher, H. I.; Efstathiou, E.; Lara, P. N.; Yu, E. Y.; George, D. J.; Chi, K. N.; Saad, F.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

Meeting Abstract

Tabernero, J.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Loupakis, F.; Sang Hong, Y.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Meeting Abstract

Yau, T.; Park, J. W.; Finn, R. S.; Cheng, A. L.; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K. H.; Harding, J. J.; Merle, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2

Meeting Abstract

Doebele, R. C.; Dziadziuszko, R.; Drilon, A.; Shaw, A.; Wolf, J.; Farago, A. F.; Dennis, L.; Riehl, T.; Simmons, B.; Wu, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save